Tag Archives: Bluebird Bio

December, 2018

August, 2018

  • 23 August

    bluebird bio and Gritstone Oncology Collaborate to Develop Novel Cancer Cell Therapies

    CAMBRIDGE, Mass. & EMERYVILLE, Calif.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell …

  • 6 August

    Regeneron and bluebird bio Collaborate for Development of New Cell Therapies for Cancer

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and bluebird bio, Inc. (NASDAQ: BLUE) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human …

May, 2018

December, 2017

November, 2017

October, 2017

  • 6 October

    Bluebird Gene Therapy Halts Progression of Cerebral Adrenoleukodystrophy

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational …